MIF:: a new cytokine link between rheumatoid arthritis and atherosclerosis

被引：292

作者：

Morand, EF

Leech, M

Jürgen, B

机构：

[1] Monash Inst Med Res, Ctr Inflammatory Dis, Clayton, Vic 3168, Australia

[2] RWTH Univ Hosp, Inst Biochem, Dept Biochem & Mol Cell Biol, D-52074 Aachen, Germany

来源：

NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 05期

关键词：

D O I：

10.1038/nrd2029

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Macrophage migration inhibitory factor (MIF) is well established as a key cytokine in immuno-inflammatory diseases such as rheumatoid arthritis. Inflammation is now also recognized as having a crucial role in atherosclerosis, and recent evidence indicates that MIF could also be important in this disease. Here, we review the role of MIF in rheumatoid arthritis and atherosclerosis, discuss the ways in which MIF and its relationship with glucocorticoids could link these diseases, and consider the potential of MIF as a new therapeutic target for small-molecule and antibody-based anti-cytokine drugs.

引用

收藏

页码：399 / 410

页数：12

相关论文

共 132 条

[11] MIF IS A PITUITARY-DERIVED CYTOKINE THAT POTENTIATES LETHAL ENDOTOXEMIA [J].

BERNHAGEN, J ;

CALANDRA, T ;

MITCHELL, RA ;

MARTIN, SB ;

TRACEY, KJ ;

VOELTER, W ;

MANOGUE, KR ;

CERAMI, A ;

BUCALA, R .

NATURE, 1993, 365 (6448) :756-759

[12] An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction [J].

Bernhagen, J ;

Bacher, M ;

Calandra, T ;

Metz, CN ;

Doty, SB ;

Donnelly, T ;

Bucala, R .

JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (01) :277-282

[13] Targeting IL-1 in inflammatory disease: New opportunities for therapeutic intervention [J].

Braddock, M ;

Quinn, A .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (04) :1-10

[14] Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF) [J].

Burger-Kentischer, A ;

Göbel, H ;

Kleemann, R ;

Zerneckee, A ;

Bucala, R ;

Leng, L ;

Finkelmeier, D ;

Geiger, G ;

Schaefer, HE ;

Schober, A ;

Weber, C ;

Brunner, H ;

Rütten, H ;

Ihling, C ;

Bernhagen, J .

ATHEROSCLEROSIS, 2006, 184 (01) :28-38

[15] Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis [J].

Burger-Kentischer, A ;

Goebel, H ;

Seder, R ;

Fraedrich, G ;

Schaefer, HE ;

Dimmeler, S ;

Kleemann, R ;

Bernhagen, J ;

Ihling, C .

CIRCULATION, 2002, 105 (13) :1561-1566

[16] MACROPHAGE IS AN IMPORTANT AND PREVIOUSLY UNRECOGNIZED SOURCE OF MACROPHAGE-MIGRATION INHIBITORY FACTOR [J].

CALANDRA, T ;

BERNHAGEN, J ;

MITCHELL, RA ;

BUCALA, R .

JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (06) :1895-1902

[17] Protection from septic shock by neutralization of macrophage migration inhibitory factor [J].

Calandra, T ;

Echtenacher, B ;

Le Roy, D ;

Pugin, J ;

Metz, CN ;

Hültner, L ;

Heumann, D ;

Männel, D ;

Bucala, R ;

Glauser, MP .

NATURE MEDICINE, 2000, 6 (02) :164-170

[18] MIF AS A GLUCOCORTICOID-INDUCED MODULATOR OF CYTOKINE PRODUCTION [J].

CALANDRA, T ;

BERNHAGEN, J ;

METZ, CN ;

SPIEGEL, LA ;

BACHER, M ;

DONNELLY, T ;

CERAMI, A ;

BUCALA, R .

NATURE, 1995, 377 (6544) :68-71

[19] JAB1/CSN5 and the COP9 signalosome - A complex situation [J].

Chamovitz, DA ;

Segal, D .

EMBO REPORTS, 2001, 2 (02) :96-101

[20] Mechanisms of disease - The many roles of chemokines and chemokine receptors in inflammation [J].

Charo, IF ;

Ransohoff, RM .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :610-621

← 1 2 3 4 5 6 7 8 9 10 →